About nanoComposix
Founded in 2004, nanoComposix, a Fortis Life Sciences company, develops and manufactures engineered nanoparticles for research, diagnostic and industrial applications. As part of Fortis Life Sciences, the company specialises in the synthesis, characterisation and scale-up of highly uniform metal, metal oxide, silica, magnetic and polymer nanoparticles designed to provide consistent performance and reproducible results. Its expertise supports researchers developing diagnostic assays, therapeutic platforms and advanced materials, with capabilities spanning custom nanoparticle design, process development and commercial-scale manufacturing. Products are supported by detailed characterisation data to help researchers evaluate particle properties and optimise downstream applications in nanomedicine, biosensing, materials science and analytical research.
The company’s portfolio includes gold and silver nanoparticles, gold nanorods, gold nanoshells, silica nanoparticles, magnetic nanoparticles and functionalised nanoparticle reagents for conjugation and assay development. Product families such as BioReady™, BioPure™ and NanoXact™ are used in workflows including lateral flow assay development, diagnostics, molecular detection, biosensor design, drug delivery research and nanoparticle characterisation. nanoComposix also provides custom synthesis and contract development and manufacturing services, including support for regulated environments with ISO 13485-compliant capabilities.
Europa Biosite subsidiaries distribute nanoComposix products across Belgium, Estonia, Finland, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Sweden, Switzerland and the United Kingdom.